Application of anacardic acid in preparing anti-angiogenic drugs

An angiogenesis and anacardic acid technology, applied in the field of application of anacardic acid in the preparation of anti-angiogenesis drugs

Active Publication Date: 2010-02-17
BIORAY LABORATORIES INC
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are no reports on the effect of anacardic acid on angiogenesis at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of anacardic acid in preparing anti-angiogenic drugs
  • Application of anacardic acid in preparing anti-angiogenic drugs
  • Application of anacardic acid in preparing anti-angiogenic drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Anacardic acid inhibits the proliferation of human umbilical vein endothelial cells (HUVEC)

[0028] Purpose and principle:

[0029] The endothelial cell proliferation experiment used MTS assay. MTS assay is an indirect measurement method that uses colorimetry to measure the number of living cells. CellTiter The Aqueous single-solution reagent contains a tetrazole compound (internal salt; MTS) and an electron coupling reagent (ethithiophenazine; PES). MTS can be activated by dehydrogenase in metabolically active cells to produce particles soluble in tissue culture medium. The absorbance of the product measured at 490nm is directly proportional to the number of living cells in the culture.

[0030] Method: Add human umbilical vein endothelial cells to a 96-well plate, set up a control group and a sample group. The control group is added with solvent, and the sample group is added with different concentrations of anacardic acid. After 48-72 hours of incubation, the...

Embodiment 2

[0032] Example 2: Anacardic acid inhibits migration of human umbilical vein endothelial cells (HUVEC)

[0033] Purpose and principle: Under the action of vascular endothelial cell growth factor (VEGF), human umbilical vein endothelial cells can migrate to scratched areas without cells. By observing the amount of endothelial cells that migrated into the scratch area, it was evaluated whether anacardic acid has the ability to inhibit the migration of human microvascular endothelial cells.

[0034] Method: Add human microvascular endothelial cells to the 6-well plate. When it is about full, draw a cross-shaped scratch with the tip, wash the scored cells with PBS, and add VEGF 165 And culture media containing different drug concentrations until the VEGF group is full.

[0035] Results and evaluation: such as figure 2 As shown, observation and photographing under a microscope showed that the migration of human umbilical vein endothelial cells was inhibited compared with the control group...

Embodiment 3

[0036] Example 3: Anacardic acid inhibits the migration of Boyden cells of human umbilical vein endothelial cells (HUVEC)

[0037] Purpose and principle: Boyden chamber is used to study the chemotaxis of leukocytes. This research is based on the separation of the chamber into two parts by a micropore. The cells are placed on the upper part and the lower part contains chemokines. Under the induction of the chemokines, the upper cells can migrate through the micromembrane pores to the bottom of the membrane and attach to the back of the membrane. Cells can pass through the polycarbonate filter membrane under the induction of growth factors. This experiment can detect the effect of drugs on the resistance to migration of endothelial cells.

[0038] Method: Coat the chamber with gelatin, discard the gelatin after incubation, and wash three times with PBS. Add endothelial cell culture medium containing serum and VEGF to the 24-well plate outside the chamber. Connect cells to the chamb...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of anacardic acid in preparing anti-angiogenic drugs. The anti-angiogenic drugs prepared from anacardic acid of the invention can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissueangiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of anacardic acid and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

Description

Technical field [0001] The present invention relates to a new anti-angiogenesis Chinese herbal medicine monomer anacardic acid and the application of the compound in the treatment and prevention of angiogenesis-related diseases. Background technique [0002] Angiogenesis refers to the process by which mature vascular endothelial cells that have previously existed in the tissue proliferate and migrate to form new progeny blood vessels in the form of sprouting or embedding. Angiogenesis is in cancer, rheumatoid arthritis, diabetic retinopathy, age-related macular degeneration, leukemia, atherosclerosis, endometritis, psoriasis, uterine leiomyoma, benign prostatic hypertrophy and other dozens of diseases and inflammations Both reaction and wound healing play a key role. [0003] Cancer is a major killer of humans. There are many types of tumor cells, which are prone to mutations and drug resistance. Traditional chemotherapy and radiotherapy can cause great damage to normal cells. Stu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/192A61P35/00A61P35/02A61P19/02A61P27/02A61P17/06
Inventor 易正芳吴媛媛贺利军张晓丽张京卢彬彬赖力刘明耀
Owner BIORAY LABORATORIES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap